Answers are grounded in this paper and cite their sources.
Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: